西沙必利对慢性肾衰竭患者消化道症状及胃肠激素的影响

Effects of cisapride on symptoms of digestive and gastrointestinal hormones in chronic renal failure patients

目的研究西沙必利对慢性肾衰竭患者消化道症状的治疗效果，及其对患者胃肠激素的影响。方法选取2017年9月到2017年11月在天津市第三中心医院进行治疗的慢性肾衰竭患者46例，所有患者均给予基础疾病的常规治疗，然后按随机数字法分为两组，其中23例患者在常规治疗的基础上加用西沙必利进行治疗（研究组），其余23例患者为对照组。对比两组患者治疗前后消化道症状、血清生长抑素（SS）、胃动素（MOT）、血管活性肠肽（VIP）和。肾功能变化。结果治疗后，研究组患者酸反流、恶心呕吐、腹胀、嗳气以及硬粪评分显著低于治疗前（均P〈0．05），且显著低于对照组治疗后（均P〈0．05）；两组患者治疗前后SS和VIP差异无统计学意义（P〉0．05），对照组治疗后MOT亦无明显变化（P〉0．05），但研究组患者治疗后MOT显著下降（P〈0．05），且显著低于对照组治疗后（P〈0．05）；两组患者组间比较治疗前后Scr、Ccr和BUN差异均无统计学意义（P〉0．05）。结论对于慢性肾衰竭患者，在常规基础疾病治疗的基础上加用西沙必利可以改善其消化道症状效果，同时降低患者血清胃动素含量。

Objective To study the effects of cisapride on symptoms of digestive and gastrointestinal hormones in chronic renal failure patients. Methods There were 46 cases of chronic renal failure patients in this paper, all patients were given routine treatment of the underlying disease and were randomly divided into two groups. 23 patients were additionally treated with cisapride as research group, and the others as control group. The gastrointestinal symptoms, serum somatostatin （SS）, motilin （MOT） and vasoaetive intestinal peptide （VIP） and other gastrointestinal hormones and renal function in two groups of patients were compared before and after treatment. Results The score of acid reflux, nausea, vomiting, abdominal distension, belching and other symptoms of hard feces and other gastrointestinal after treatment were significantly lower than that before treatment in research group and after treatment in control group （all P 〈 0.05）. There was no significant change between before and after treatment in SS and VIP of two group （all P 〉 0.05）, and MOT in control group （P 〉 0.05）, but the MOT in research group was decreased significantly（P 〈 0.05）. There was no significant difference in Scr, Ccr and BUN between the control and research group after treatment （all P 〉 0.05）.Conclusion Conventional treatment combined with cisapride can improve the effect of gastrointestinal symptoms in patients with chronic renal failure, while reducing serum motilin level.